Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
Rebecca Lu, MSN, FNP-C, Ashley Morphey, RN, MSN, CCRP, FelIcia Diaz, MSN, APRN, FNP-BC, AOCNP®, Jessica Chen, RN, MSN, OCN®, FNP-C, Azadeh Razmandi, OD, FAAO, and Tiffany Richards, PhD, ANP-BC, AOCNP®
From The University of Texas MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Rebecca Lu, MSN, FNP-C,
1515 Holcombe Boulevard, Houston, TX 77030
J Adv Pract Oncol 2023;14(4):300–306 |
© 2023 Harborside™
While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for more treatment modalities remains, as patients who are refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies have a median survival of only 5.8 to 13 months. Belantamab mafodotin, a first-in-class antibody-drug conjugate, was approved by the US Food and Drug Administration in 2020 for patients with relapsed or refractory myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It produced an overall response rate of 31%, and the median progression-free survival was 2.9 months when administered as a single agent. While generally well tolerated, ocular toxicities were a notable adverse event reported. In this article, we discuss the response data, toxicity profile including ocular toxicities, and treatment management.
For access to the full length article, please sign in